ClinicalTrials.gg
CompletedNCT05369390Updated Jun 15, 2025

A Research Study on How NNC0487-0111 Works in People With Overweight or Obesity

A Phase 1 interventional study of NNC0487-0111 A and NNC0487-0111 B in Obesity, sponsored by Novo Nordisk A/S. Completed at 2 sites in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-15.

Sponsored by Novo Nordisk A/S · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jan 2024, 2 years 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
144
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 207 studies in Obesity by Novo Nordisk A/S — 48 open to participants now, 66 under way, 26 of them phase 3. Obesity · Novo Nordisk A/S.

Enrollment
81st of 166
144 · median 138
Started
2022
with 12 others
Phase 1
85 of 207
22 open now
Registered
87th of 207
by date

Among the 207 studies in Obesity by Novo Nordisk A/S, this one is the 81st largest by enrollment of the 166 interventional ones that give a count, is one of 13 that started in 2022, is one of 85 in phase 1, and was the 87th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

48 of the 207 studies in Obesity by Novo Nordisk A/S are open now, in 12 countries. Recruiting first, the newest first:

43 more — sign in →

By country, each count listing its studies:

All 48 open studies →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 207 studies in Obesity by Novo Nordisk A/S, or all of them as a file.
02

Study summary

NNC0487-0111 is a new medicine similar to 2 hormones that are produced in human body: amylin and glucagon-like peptide-1 (GLP-1). Both hormones work like body's own hormones and help the body to feel full. This study tests if the study medicine is safe and to find out how the medicine works in humans. This study also look at how the study medicine affects body weight and how to improve the treatment of people with overweight, obesity or related diseases.

This study will have 4 parts: Part A, B, C and D. Part A: This is planned to consist of five groups, one additional group may be added. Each group will include 8 participants, with 6 participants being randomised to receive a single dose of NNC0487-0111 A and 2 participants randomised to receive placebo. The dosing within each group will be sequential, i.e., 2 sentinel participants (1 on active and 1 on placebo).

Part B: This is planned to consist of three groups, one additional group may be added. Each group will include 12 participants, with 9 participants being randomised to receive NNC0487-0111 A and 3 participants randomised to receive placebo once daily for 10 days. The dosing within each group will be sequential. For the first group, 4 sentinel participants (3 on active and 1 on placebo) will be dosed followed by a safety observation period of 7 days (168 hours), before dosing of the remaining participants in the group will be initiated. For the remaining groups, 4 sentinel participants (3 on active and 1 on placebo) will be dosed followed by a safety observation period of at least 36 hours before dosing of the remaining participants in the group will be initiated.

Part C and D are matching regarding planned visits and procedures, but the study interventions in Part D (NNC0487-0111 B) differ from Part A, B and C (NNC0487-0111 A). Each part is planned to consist of one group, although one additional group may be added. Each group will include 20 participants, with 16 participants being randomised to receive active treatment and 4 participants randomised to receive placebo once-daily for 12 weeks. The dosing will be sequential, i.e., 4 sentinel participants (3 on active and 1 on placebo) will be dosed followed by a safety observation period of at least 36 hours before dosing of the remaining participants in the cohort will be initiated. The remaining participants will be dosed in smaller groups of 8 participants separated by a safety observation period of at least 36 hours.

A safety evaluation will be made between dosing of participants within a group and before moving on to a higher dose.

03

Conditions studied

  • Obesity

Keywords

  • overweight
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Part A and B:

  • Male or female aged 18-55 years (both inclusive) at time of signing
  • (BMI) of 25.0 to 34.9 kilogram per square meter (kg/m\^2) (both inclusive) at screening
  • Considered eligible based on the medical history, physical examination, and the results of vital signs, and clinical laboratory tests performed during the screening visit, as judged by the investigator.

Part C and D:

  • Male or female aged 18-55 years (both inclusive) at time of signing informed consent
  • Body mass index (BMI) of 27.0 to 39.9 kg/m\^2 (both inclusive) at screening
  • Considered eligible based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator.

Exclusion criteria

Exclusion Criteria:

Part A and B:

  • Any disorder, which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol
  • greater than or equal to 6.5 % (48 millimoles per mole (mmol/mol)) at screening
  • Any laboratory safety parameters at screening outside the below laboratory ranges, see designated reference range documents for specific values
  • Vitamin D (25-hydroxycholecalciferol) less than 20 Nanograms per milliliter (ng/mL) (50 nano molar (NM)) at screening
  • Parathyroid hormone (PTH) outside normal range at screening
  • Total calcium outside normal range at screening
  • Amylase greater than or equal to 2 times at screening
  • Lipase greater than or equal to 2 times upper limit of normal at screening

Part C and D:

  • Any disorder, which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol
  • HbA1c greater than or equal to 6.5 % (48 mmol/mol) at screening
  • Any laboratory safety parameters at screening outside the below laboratory ranges, see designated reference range documents for specific values:
  • Vitamin D (25-hydroxycholecalciferol) less than 20 ng/mL (50 nM) at screening
  • Parathyroid hormone (PTH) outside normal range at screening
  • Total calcium outside normal range at screening
  • Amylase greater than or equal to 2 times upper limit of normal at screening
  • Lipase greater than or equal to 2 times upper limit of normal at screening
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
144 participants (actual)

Study arms

  • Experimental
    Part A: Single ascending dose (SAD)

    Participants will receive a single dose of any of the six different dose levels (1, 3, 6, 12, 25 and 50 milligrams (mg)) of NNC0487-0111 A or matching placebo in a sequential manner with the dose increasing between cohorts.

    Drug: NNC0487-0111 A · Other: Placebo A (NNC0487-0111 A)

  • Experimental
    Part B: Multiple ascending dose (MAD)

    Participants will receive NNC0487-0111 once daily for 10 days at any of the five different dose levels (3, 6, 12, 25 and 50 milligrams (mg)) of NNC0487-0111 A or matching placebo in a sequential manner with the dose increasing between cohorts.

    Drug: NNC0487-0111 A · Other: Placebo A (NNC0487-0111 A)

  • Experimental
    Part C

    Participants will receive NNC0487-0111 A or matching placebo once-daily for 12 weeks: 3 or 6 mg for weeks 1-2, 6 or 12 mg for weeks 3-4, 12 or 25 mg for weeks 5-6, 25 or 50 mg for weeks 7-8, 25 or 50 mg for weeks 9-10 and 50 or 2\*50 mg for weeks 11-12.

    Drug: NNC0487-0111 A · Other: Placebo A (NNC0487-0111 A)

  • Experimental
    Part D

    Participants will receive NNC0487-0111 B or matching placebo once-daily for 12 weeks: 3 or 6 mg for weeks 1-2, 6 or 12 mg for weeks 3-4, 12 or 25 mg for weeks 5-6, 25 or 50 mg for weeks 7-8, 25 or 50 mg for weeks 9-10 and 50 or 2\*50 mg for weeks 11-12.

    Drug: NNC0487-0111 B · Other: Placebo B (NNC0487-0111 B)

Interventions

  • Participants will receive NNC0487-0111 A tablet once daily.

  • Participants will receive NNC0487-0111 B tablet once daily.

  • OtherPlacebo B (NNC0487-0111 B)

    Participants will receive placebo matched to NNC0487-0111 B tablet once daily.

  • OtherPlacebo A (NNC0487-0111 A)

    Participants will receive placebo matched to NNC0487-0111 A tablet once daily.

06

What researchers measure

Primary outcomes

  1. Number of treatment emergent adverse events (TEAE)

    Number of events

    Time frame: Part A: From pre-dose on Day 1 to 22 days; Part B: From pre-dose on Day 1 to 31 days; Part C and D: From pre-dose on Day 1 to 105 days

Secondary outcomes

  1. Part A: AUC0-∞,SD; the area under the NNC0487-0111 plasma concentration-time curve from time 0 to infinity after a single dose

    Hours\*Nanomoles per liter (h\*nmol/L)

    Time frame: From pre-dose on Day 1 until completion of the end of study visit (Day 22)

  2. Part A: Cmax,SD; the maximum plasma concentration of NNC0487- 0111 after a single dose

    Nanomoles per liter (nmol/L)

    Time frame: From pre-dose on Day 1 until completion of the end of study visit (Day 22)

  3. Part B: AUC0-24h,MD; the area under the NNC0487-011 plasma concentration-time curve from time 0 to 24 hours after last multiple dose

    h\*nmol/L

    Time frame: From pre-dose on Day 10 until Day 11 (24 hours post-dose)

  4. Part B: Cmax,MD; the maximum plasma concentration of NNC0487- 0111 after last multiple dose

    nmol/L

    Time frame: From pre-dose on Day 10 until Day 22

  5. Part C and D: AUC0-24h,MD; the area under the NNC0487-011 plasma concentration-time curve from time 0 to 24 hours after last multiple dose

    h\*nmol/L

    Time frame: From pre-dose on Day 84 until Day 85 (24 hours post-dose)

  6. Part C and D: Cmax,MD; the maximum plasma concentration of NNC0487- 0111 after last multiple dose

    nmol/L

    Time frame: From pre-dose on Day 84 until completion of the end of study visit (Day 105)

07

Study locations

2 sites
  • ICON Early Phase Services, LLC
    San Antonio, Texas 78209, United States
  • Novo Nordisk Investigational Site
    San Antonio, Texas 78209, United States
08

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2022 to primary completion in Jan 2024, 19 months.

Of 335 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 19 months is above that.

Counting every sponsor, half of 440 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
May 4, 2022
First posted
May 11, 2022
StartActual
May 11, 2022
Primary completionActual
Jan 9, 2024
CompletionActual
Jan 9, 2024
Last update
Jun 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05369390
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
May 11, 2022
Start date
May 11, 2022
Primary completion
Jan 9, 2024
Completion
Jan 9, 2024
Last update
Jun 15, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: NNC0487-0111

Start the discussion